Article

Nicotinic α4β2 receptor imaging agents. Part III. Synthesis and biological evaluation of 3-(2-(S)-azetidinylmethoxy)-5-(3'-18F-fluoropropyl)pyridine (18F-nifzetidine).

Department of Radiology, University of California-San Diego, CA, USA.
Nuclear Medicine and Biology (Impact Factor: 2.41). 08/2011; 38(8):1183-92. DOI: 10.1016/j.nucmedbio.2011.05.005
Source: PubMed

ABSTRACT Thalamic and extrathalamic nicotinic α4β2 receptors found in the brain have been implicated in Alzheimer's disease, Parkinson's disease, substance abuse and other disorders. We report here the development of 3-(2-(S)-azetidinylmethoxy)-5-(3'-fluoropropyl)pyridine (nifzetidine) as a new putative high-affinity antagonist for nicotinic α4β2 receptors. Nifzetidine in rat brain homogenate assays containing α4β2 sites labeled with (3)H-cytisine exhibited a binding affinity: Ki=0.67 nM. The fluorine-18 analog, 3-(2-(S)-azetidinylmethoxy)-5-(3'-(18)F-fluoropropyl)pyridine ((18)F-nifzetidine), was synthesized in 20%-40% yield, and apparent specific activity was estimated to be above 2 Ci/μmol. Rat brain slices indicated selective binding of (18)F-nifzetidine to thalamus, subiculum, striata, cortex and other regions consistent with α4β2 receptor distribution. This selective binding was displaced >85% by 150 μM nicotine. Positron emission tomography (PET) imaging studies of (18)F-nifzetidine in anesthetized rhesus monkey showed slow uptake in the various brain regions. Retention of (18)F-nifzetidine was maximal in the thalamus and lateral geniculate followed by regions of the temporal and frontal cortex. Cerebellum showed the least uptake. Thalamus to cerebellum ratio was about 2.3 at 180 min postinjection and continued to rise. (18)F-Nifzetidine shows promise as a new PET imaging agent for α4β2 nAChR. However, the slow kinetics suggests a need for >3-h PET scans for quantitative studies of the α4β2 nAChRs.

Download full-text

Full-text

Available from: Jogeshwar Mukherjee, Jul 04, 2015
0 Followers
 · 
125 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Imaging agents for nicotinic α4β2 receptors in the brain have been under way for studying various CNS disorders. Previous studies from our laboratories have reported the successful development of agonist, (18)F-nifene. In attempts to develop potential antagonists, (18)F-nifrolidine and (18)F-nifzetidine were previously reported. Further optimization of these fluoropropyl derivatives has now been carried out resulting in 3-(2-(S)-3,4-dehydropyrrolinylmethoxy)-5-(3'-Fluoropropyl)pyridine (nifrolene) as a new high affinity agent for nicotinic α4β2 receptors. Nifrolene in rat brain homogenate assays - labeled with (3)H-cytisine - exhibited a binding affinity of 0.36nM. The fluorine-18 analog, (18)F-nifrolene, was synthesized in approximately 10%-20% yield and specific activity was estimated to be >2000Ci/mmol. Rat brain slices indicated selective binding to anterior thalamic nuclei, thalamus, subiculum, striata, cortex and other regions consistent with α4β2 receptor distribution. This selective binding was displaced >90% by 300μM nicotine. Thalamus to cerebellum ratio (>10) was the highest for (18)F-nifrolene with several other regions showing selective binding. In vivo rat PET studies exhibited rapid uptake of (18)F-nifrolene in the brain with specific retention in the thalamus and other brain regions while clearing out from the cerebellum. Thalamus to cerebellum ratio value in the rat was >4. Administration of nicotine caused a rapid decline in the thalamic (18)F-nifrolene suggesting reversible binding to nicotinic receptors. PET imaging studies of (18)F-nifrolene in anesthetized rhesus monkey revealed highest binding in the thalamus followed by regions of the lateral cingulated and temporal cortex. Cerebellum showed the least binding. Thalamus to cerebellum ratio in the monkey brain was >3 at 120min. These ratios of (18)F-nifrolene are higher than measured for (18)F-nifrolidine and (18)F-nifzetidine. (18)F-Nifrolene thus shows promise as a new PET imaging agent for α4β2 nAChR.
    Nuclear Medicine and Biology 11/2012; 40(1). DOI:10.1016/j.nucmedbio.2012.09.009 · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cerebral neuronal nicotinic acetylcholine receptors (nAChRs) are implicated in various neurophysiological processes and in the pathophysiology and/or treatment strategies of various disorders. Positron emission tomography (PET) imaging of nAChR and, especially, the most prominent cerebral subtype α4β2-nAChR is important in smoking, epilepsy, attention deficit hyperactivity disorder, depression, schizophrenia, cognition, behavior, memory, and in research involving aging, cognitive impairments, and dementia. Most human α4β2-nAChR PET imaging has been performed with 2-[(18) F]FA, but slow brain kinetics is the substantial drawback of 2-[(18) F]FA that precludes widespread PET imaging research of nAChR in humans. Development of a better PET radioligand for α4β2-nAChR was a focus of substantial investigation that has been thoroughly reviewed (up to 2009) previously. This article attempts to summarize the peer-reviewed publications of the most recent development and preclinical studies of novel α4β2-nAChR PET radioligands with improved brain kinetics and first human studies with one of these radioligands ([(18) F]AZAN).
    Journal of Labelled Compounds 03/2013; 56(3-4):159-166. DOI:10.1002/jlcr.3020